Abilify Mycite Kit is a drug owned by Otsuka Pharmaceutical Co Ltd. It is protected by 38 US drug patents filed from 2018 to 2022. Out of these, 31 drug patents are active and 7 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 19, 2034. Details of Abilify Mycite Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9359302 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) |
Expired
|
| US8580796 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) |
Expired
|
| US8642760 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10097388 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | Active |
| US9787511 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | Active |
| US9270503 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | Active |
| US9268909 | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(8 years from now) | Active |
| US9577864 | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
Oct, 2033
(8 years from now) | Active |
| US10517507 | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(7 years from now) | Active |
| US9320455 | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(6 years from now) | Active |
| US11229378 | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(6 years from now) | Active |
| US8547248 | Implantable zero-wire communications system |
Dec, 2030
(5 years from now) | Active |
| US8258962 | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(5 years from now) | Active |
| US8961412 | In-body device with virtual dipole signal amplification |
Nov, 2030
(5 years from now) | Active |
| US9941931 | System for supply chain management |
Nov, 2030
(5 years from now) | Active |
| US11464423 | In-body power source having high surface area electrode |
Sep, 2030
(5 years from now) | Active |
| US8114021 | Body-associated receiver and method |
Jun, 2030
(5 years from now) | Active |
| US8545402 | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(5 years from now) | Active |
| US8847766 | Pharma-informatics system |
Mar, 2030
(4 years from now) | Active |
| US9149577 | Body-associated receiver and method |
Dec, 2029
(4 years from now) | Active |
| US8718193 | Active signal processing personal health signal receivers |
Dec, 2029
(4 years from now) | Active |
| US9433371 | In-body device with virtual dipole signal amplification |
Sep, 2029
(4 years from now) | Active |
| US8945005 | Controlled activation ingestible identifier |
Aug, 2029
(4 years from now) | Active |
| US10441194 | Ingestible event marker systems |
Jul, 2029
(4 years from now) | Active |
| US8956288 | In-body power source having high surface area electrode |
Jul, 2029
(4 years from now) | Active |
| US8674825 | Pharma-informatics system |
Apr, 2029
(3 years from now) | Active |
| US9258035 | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(3 years from now) | Active |
| US9060708 | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(3 years from now) | Active |
| US9119554 | Pharma-informatics system |
Dec, 2028
(3 years from now) | Active |
| US9444503 | Active signal processing personal health signal receivers |
Nov, 2027
(2 years from now) | Active |
| US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(1 year, 10 months from now) | Active |
| US7978064 | Communication system with partial power source |
Sep, 2026
(1 year, 4 months from now) | Active |
| US9125939 | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(1 year, 3 months from now) | Active |
| US11476952 | Pharma-informatics system |
Apr, 2026
(1 year, 6 days from now) | Active |
| US8017615 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(10 months ago) |
Expired
|
| US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(1 year, 3 months ago) |
Expired
|
| US9089567 | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(3 years ago) |
Expired
|
| US7053092 | 5-HT1a receptor subtype agonist |
Jan, 2022
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Abilify Mycite Kit's patents.
Latest Legal Activities on Abilify Mycite Kit's Patents
Given below is the list of recent legal activities going on the following patents of Abilify Mycite Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 15 Jul, 2024 | US9359302 |
| Patent eCofC Notification | 21 May, 2024 | US9149577 |
| Mail Patent eCofC Notification | 21 May, 2024 | US9149577 |
| Email Notification Critical | 21 May, 2024 | US9149577 |
| Recordation of Patent eCertificate of Correction | 21 May, 2024 | US9149577 |
| Post Issue Communication - Certificate of Correction | 01 May, 2024 | US9149577 |
| Mail Certificate of Correction Memo | 30 Apr, 2024 | US9149577 |
| Certificate of Correction Memo | 29 Apr, 2024 | US9149577 |
| Email Notification Critical | 24 Apr, 2024 | US9149577 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US9149577 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Abilify Mycite Kit and ongoing litigations to help you estimate the early arrival of Abilify Mycite Kit generic.
Abilify Mycite Kit's Litigations
Abilify Mycite Kit been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 17, 2016, against patent number US9125939. The petitioner Alkermes Pharma Ireland Limited, challenged the validity of this patent, with Otsuka Pharmaceutical Co., Ltd. as the respondent. Click below to track the latest information on how companies are challenging Abilify Mycite Kit's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9125939 | November, 2016 |
Terminated-Denied
(04 May, 2017) | Otsuka Pharmaceutical Co., Ltd. | Alkermes Pharma Ireland Limited |
FDA has granted some exclusivities to Abilify Mycite Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Abilify Mycite Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Abilify Mycite Kit.
Exclusivity Information
Abilify Mycite Kit holds 2 exclusivities. All of its exclusivities have expired in 2020. Details of Abilify Mycite Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Several oppositions have been filed on Abilify Mycite Kit's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Abilify Mycite Kit's generic, the next section provides detailed information on ongoing and past EP oppositions related to Abilify Mycite Kit patents.
Abilify Mycite Kit's Oppositions Filed in EPO
Abilify Mycite Kit has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 04, 2007, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP02782507A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP04785621A | Sep, 2017 | Generics [UK] Ltd | Revoked |
| EP08000358A | May, 2017 | Bülle Dr., Jan | Revoked |
| EP08000358A | May, 2017 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP08000358A | May, 2017 | CHEMO IBERICA, S.A. | Revoked |
| EP08000358A | Apr, 2017 | Pharmaceutical Works Polpharma | Revoked |
| EP04002427A | Jan, 2011 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
| EP02782507A | Jan, 2007 | Ratiopharm GmbH | Revoked |
| EP02782507A | Jan, 2007 | EGIS Gyógyszergyár Nyrt | Revoked |
| EP02782507A | Jan, 2007 | Pharmaceutical Works POLPHARMA | Revoked |
| EP02782507A | Jan, 2007 | Fermion Oy | Revoked |
| EP02782507A | Jan, 2007 | Teva Pharmaceutical Industries Ltd. | Revoked |
US patents provide insights into the exclusivity only within the United States, but Abilify Mycite Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Abilify Mycite Kit's family patents as well as insights into ongoing legal events on those patents.
Abilify Mycite Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Abilify Mycite Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 19, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Abilify Mycite Kit Generic API suppliers:
Aripiprazole is the generic name for the brand Abilify Mycite Kit. 28 different companies have already filed for the generic of Abilify Mycite Kit, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Abilify Mycite Kit's generic
Alternative Brands for Abilify Mycite Kit
Abilify Mycite Kit which is used for acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder (MDD), and treatment of schizophrenia., has several other brand drugs in the same treatment category and using the same active ingredient (Aripiprazole). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Alkermes Inc |
| |||||||
| Indivior |
| |||||||
| Intra-cellular |
| |||||||
| Janssen Pharms |
| |||||||
| Otsuka |
| |||||||
| Otsuka Pharm Co Ltd |
| |||||||
| Sunovion Pharms Inc |
| |||||||
| Teva |
| |||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Aripiprazole. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Xiamen Lp Pharm Co |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Aripiprazole, Abilify Mycite Kit's active ingredient. Check the complete list of approved generic manufacturers for Abilify Mycite Kit
About Abilify Mycite Kit
Abilify Mycite Kit is a drug owned by Otsuka Pharmaceutical Co Ltd. It is used for acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder (MDD), and treatment of schizophrenia. Abilify Mycite Kit uses Aripiprazole as an active ingredient. Abilify Mycite Kit was launched by Otsuka in 2017.
Approval Date:
Abilify Mycite Kit was approved by FDA for market use on 13 November, 2017.
Active Ingredient:
Abilify Mycite Kit uses Aripiprazole as the active ingredient. Check out other Drugs and Companies using Aripiprazole ingredient
Treatment:
Abilify Mycite Kit is used for acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder (MDD), and treatment of schizophrenia.
Dosage:
Abilify Mycite Kit is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 15MG | TABLET | Discontinued | ORAL |
| 5MG | TABLET | Discontinued | ORAL |
| 20MG | TABLET | Discontinued | ORAL |
| 30MG | TABLET | Discontinued | ORAL |
| 2MG | TABLET | Discontinued | ORAL |
| 10MG | TABLET | Discontinued | ORAL |